Latest & greatest articles for sertraline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sertraline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sertraline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sertraline

21. Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents

Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents Article Text Therapeutics Short term CBT and sertraline, alone or in combination, reduce

2009 Evidence-Based Mental Health

22. A combination of cognitive?behavioural therapy and sertraline reduced anxiety in children more than either treatment alone

A combination of cognitive?behavioural therapy and sertraline reduced anxiety in children more than either treatment alone A combination of cognitive–behavioural therapy and sertraline reduced anxiety in children more than either treatment alone | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A combination of cognitive–behavioural therapy and sertraline reduced anxiety in children more than either treatment alone Article Text

2009 Evidence-Based Medicine

23. Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response

Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) disorder symptoms compared with sertraline, but not response Article Text Therapeutics Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse

2008 Evidence-Based Mental Health

24. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. Full Text available with Trip Pro

Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. Anxiety disorders are common psychiatric conditions affecting children and adolescents. Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown efficacy in treating these disorders, little is known about their relative or combined efficacy.In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation (...) anxiety disorder, generalized anxiety disorder, or social phobia to receive 14 sessions of cognitive behavioral therapy, sertraline (at a dose of up to 200 mg per day), a combination of sertraline and cognitive behavioral therapy, or a placebo drug for 12 weeks in a 2:2:2:1 ratio. We administered categorical and dimensional ratings of anxiety severity and impairment at baseline and at weeks 4, 8, and 12.The percentages of children who were rated as very much or much improved on the Clinician Global

2008 NEJM Controlled trial quality: uncertain

25. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Full Text available with Trip Pro

Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Armstrong E P, Skrepnek G H, Erder M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two selective serotonin re-uptake inhibitors (SSRIs), escitalopram and sertraline, for the treatment of major depressive disorder (MDD). Escitalopram was initially given at 10 mg/day; the dose was assumed to increase to 20 mg/day if the patient did not respond to the initial dose. Sertraline was initially given at 50 mg/day

2007 NHS Economic Evaluation Database.

26. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. Full Text available with Trip Pro

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 (...) weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory

2006 NEJM Controlled trial quality: uncertain

27. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment

2006 Evidence-Based Mental Health

28. Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Full Text available with Trip Pro

Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline improves depression scores in the elderly in the short term, regardless of medical comorbidity status Article Text Therapeutics Sertraline improves

2005 Evidence-Based Mental Health

29. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Full Text available with Trip Pro

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Article Text Therapeutics Venlafaxine offers no benefit over sertraline

2005 Evidence-Based Mental Health

30. Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Full Text available with Trip Pro

Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline reduced the severity of patients’ depressive symptoms in major depressive disorder Article Text Therapeutics Sertraline reduced the severity of patients’ depressive symptoms in major

2005 Evidence-Based Medicine

31. Sertraline improves symptoms in children and adolescents with major depressive disorder Full Text available with Trip Pro

Sertraline improves symptoms in children and adolescents with major depressive disorder Sertraline improves symptoms in children and adolescents with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline improves symptoms in children and adolescents with major depressive disorder Article Text Therapeutics Sertraline improves symptoms in children and adolescents with major depressive disorder Free Erin B

2005 Evidence-Based Mental Health

32. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction

Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction O'Connor C M, Glassman A H, Harrison D J Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of 24 weeks' sertraline, a selective serotonin reuptake inhibitor, for the treatment of depressive disorders in patients with unstable angina (UA) or a recent myocardial infarction (MI). Sertraline was initially given at a dosage of 50

2005 NHS Economic Evaluation Database.

33. The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia Full Text available with Trip Pro

The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia

2004 Evidence-Based Mental Health

34. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Full Text available with Trip Pro

Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. The empirical literature on treatment of obsessive-compulsive disorder (OCD) in children and adolescents supports the efficacy of short-term OCD-specific cognitive-behavior therapy (CBT) or medical management with selective serotonin reuptake inhibitors. However, little is known about their relative (...) and combined efficacy.To evaluate the efficacy of CBT alone and medical management with the selective serotonin reuptake inhibitor sertraline alone, or CBT and sertraline combined, as initial treatment for children and adolescents with OCD.The Pediatric OCD Treatment Study, a balanced, masked randomized controlled trial conducted in 3 academic centers in the United States and enrolling a volunteer outpatient sample of 112 patients aged 7 through 17 years with a primary Diagnostic and Statistical Manual

2004 JAMA Controlled trial quality: predicted high

35. Sertraline as a treatment for PTSD: a systematic review and meta-analysis

Sertraline as a treatment for PTSD: a systematic review and meta-analysis Sertraline as a treatment for PTSD: a systematic review and meta-analysis Sertraline as a treatment for PTSD: a systematic review and meta-analysis Mooney P, Oakley J, Ferriter M, Travers R CRD summary This review assessed the effectiveness of sertraline for the treatment of post-traumatic stress disorder. The authors concluded that there is evidence to support the use of sertraline, but further research is required (...) . Although there were a number of limitations to this review, the authors' conclusions appear appropriately cautious. Authors' objectives To assess the effectiveness of sertraline for the treatment of post-traumatic stress disorder (PTSD). Searching PsycINFO, MEDLINE, EMBASE, the National Centre for PTSD and the Cochrane Library were searched using the reported search terms. The references of included and excluded studies were checked for further primary studies. Study selection Study designs

2004 DARE.

36. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Full Text available with Trip Pro

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents.To evaluate the efficacy and safety of sertraline compared with placebo in treatment (...) to receive a flexible dosage (50-200 mg/d) of sertraline (n = 189) or matching placebo tablets (n = 187) for 10 weeks.Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events.Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P =.001; overall mean change, -22.84 vs -20.19

2003 JAMA Controlled trial quality: predicted high

37. Sertraline treatment of major depression in patients with acute MI or unstable angina. (Abstract)

Sertraline treatment of major depression in patients with acute MI or unstable angina. Major depressive disorder (MDD) occurs in 15% to 23% of patients with acute coronary syndromes and constitutes an independent risk factor for morbidity and mortality. However, no published evidence exists that antidepressant drugs are safe or efficacious in patients with unstable ischemic heart disease.To evaluate the safety and efficacy of sertraline treatment of MDD in patients hospitalized for acute (...) single-blind placebo run-in, patients were randomly assigned to receive sertraline in flexible dosages of 50 to 200 mg/d (n = 186) or placebo (n = 183) for 24 weeks.The primary (safety) outcome measure was change from baseline in left ventricular ejection fraction (LVEF); secondary measures included surrogate cardiac measures and cardiovascular adverse events, as well as scores on the HAM-D scale and Clinical Global Impression Improvement scale (CGI-I) in the total randomized sample, in a group

2002 JAMA Controlled trial quality: predicted high

38. Sertraline: a review of its use in the management of major depressive disorder in elderly patients

Sertraline: a review of its use in the management of major depressive disorder in elderly patients Sertraline: a review of its use in the management of major depressive disorder in elderly patients Sertraline: a review of its use in the management of major depressive disorder in elderly patients Muijsers RB, Plosker GL, Noble S Authors' objectives The authors' objective appeared to be to assess the efficacy of sertraline in elderly people with major depressive disorder. The review also includes (...) evidence on the pharmacodynamics and pharmacokinetic profile of sertraline. This abstract refers only to that part of the review dealing with the therapeutic use of sertraline. Searching MEDLINE, EMBASE and AdisBase were searched from 1980 to May 2002; the search terms were reported. In addition, the bibliographies of published articles were reviewed for further studies. Bibliographic information, including contributory unpublished data, were also requested from the company developing the drug

2002 DARE.

39. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal (...) examined in the study were Sertraline (SER), a selective serotonin reuptake inhibiting (SSRI) antidepressant (starting dose: 50 mg daily); Interpersonal Psychotherapy (IPT); and a combination of both (SER-IPT) for the treatment of adult patients with dysthymia. Patients were treated for six months with one of the three alternative interventions, which was then followed by an additional naturalistic 18-month follow-up. However, patients receiving SER would continue taking their medication until the end

2002 NHS Economic Evaluation Database.

40. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. (Abstract)

Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another.To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients.Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999 (...) .Thirty-seven clinics in 2 US primary care research networks.A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview.Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate

2001 JAMA Controlled trial quality: predicted high